Fresh analysis reveals that patients who come off popular GLP-1 drugs like Wegovy and Mounjaro tend to recover lost weight at a significantly accelerated pace than those who end traditional diet and exercise regimens.
Research printed in a leading medical journal demonstrates that while obese people can lose a large proportion of their body weight while undergoing treatment, the mass returns at an estimated rate of 0.8 kg per month upon discontinuation.
"People purchasing these treatments need to be cognizant of the potential of rapid rebound weight gain when the treatment is stopped," warns lead investigator Dr. Susan Jebb.
This pace of recovery means a reversion to starting mass in about a year and a half.
Weighing Treatments
The analysis, which looked at dozens of trials involving thousands of participants, compared the results of these new drugs with conventional dieting.
Scientists point out that people who lose weight through lifestyle changes alone generally see a more gradual weight regain—approximately 0.1 kg a month—post-intervention.
Understanding the Rapid Rebound
Experts believe the way of the drugs is key to understanding the amplified rebound.
These medications copy a natural hormone called glucagon-like peptide-1, which moderates hunger.
"Sustained high doses of the hormone levels several times higher than the body's typical production may cause the system to produce less of its endogenous GLP-1, and may also lessen sensitivity to its effects," noted Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this medication results in hunger is uncontrolled, making overeating much more probable."
A Chronic Disease?
Health authorities suggest the injections for individuals with weight-linked medical conditions, accompanied by recommended lifestyle changes.
A number of clinicians contend that, given the likelihood of relapse, the therapy should be considered ongoing.
This opinion is reinforced by pharmaceutical companies, who say that the results "underscore the persistent nature of excess weight," comparing it to managing conditions like high blood pressure.
Patient Accounts
Users who have discontinued the jabs report a powerful return of hunger.
"It was like a trigger that goes on and you're instantly starving," recalled one woman.
This challenge is exacerbated if patients have not adopted sustainable dietary or behavioural changes during treatment.
Growing Interest
Figures suggest that millions of adults in the UK have used these injections in the past year, with desire being substantial.
- Adoption is more common among women than men.
- The middle-aged demographic shows the highest usage rates.
- Many access the drugs through private healthcare rather than the NHS.
Finally, experts stress that while these medications are powerful agents for weight loss, they are not a magic fix and long-term success likely depends on ongoing behavioural management.
